Nitrous oxide and perioperative cardiac morbidity (ENIGMA-II) trial: Rationale and design

Paul S Myles, Kate Leslie, Philip Peyton, Michael Paech, Andrew Benjamin Forbes, Matthew T V Chan, Daniel Sessler, Philip J Devereaux, Brendan Silbert, Konrad Jamrozik, Scott Beattie, Neil Badner, James Tomlinson, Sophia Wallace

Research output: Contribution to journalArticleResearchpeer-review

51 Citations (Scopus)

Abstract

ENIGMA-II is a 7,000-patient, international randomized trial involving patients at risk of coronary artery disease undergoing noncardiac surgery. The patients, health care providers (except for the anesthesiologists), data collectors, and outcome adjudicators are blinded to whether patients receive nitrous oxide?containing or nitrous oxide?free anesthetic. The primary outcome is a composite of death and major nonfatal events (ie, myocardial infarction, cardiac arrest, pulmonary embolism, and stroke) at 30 days after surgery.
Original languageEnglish
Pages (from-to)488 - 494.e1
Number of pages8
JournalAmerican Heart Journal
Volume157
Issue number3
DOIs
Publication statusPublished - 2009

Cite this

Myles, P. S., Leslie, K., Peyton, P., Paech, M., Forbes, A. B., Chan, M. T. V., Sessler, D., Devereaux, P. J., Silbert, B., Jamrozik, K., Beattie, S., Badner, N., Tomlinson, J., & Wallace, S. (2009). Nitrous oxide and perioperative cardiac morbidity (ENIGMA-II) trial: Rationale and design. American Heart Journal, 157(3), 488 - 494.e1. https://doi.org/10.1016/j.ahj.2008.11.015